[1]
|
Y. Sherer, M. Blank and Y. Shoenfeld, “Anti-phospholipid syndrome (APS): where does it come from ?,” Best Pract Res Clin Rehumatol, Vol 21, No. 6, 2007, pp. 1071- 1078.
|
[2]
|
E. M. Bevers, M. Galli, T. Barbui, et al., “Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin,” Thromb Haemost, Vol. 66, 1991, pp. 629-632.
|
[3]
|
S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey and R. Cervera, “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” J Thromb Haemost, Vol.4, 2006, pp. 295-306.
|
[4]
|
H. P. McNeil, R. J. Simpson, C. N. Chesterman and S.A. Krilis, “Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2- glycoprotein 1 (apolipoprotein H),” Proc Natl Acad Sci USA, Vol. 87, 1990, pp. 4120-4125.
|
[5]
|
P. L. Meroni, N. Del Papa, D. Gambini, A. Tincami and G. Balesterari, “Antiphospholipid antibodies and endothelial cells: an unending story,” Lupus, Vol. 4, 1995, pp.169-71.
|
[6]
|
D. S. Pisetsky, G. Gilkeson and E. W. St. Clair, “Systemic Lupus Erythematosus. Diagnosis and Treatment,” Med Clin North Am, Vol.81, No. 1,1997, pp.113-128.
|
[7]
|
G. S. Cooper, M.A. Dooley, E. L. Treadwell, E.W. St Clair, C. G. Parks and G.S. Gilkeson, “Hormonal, environmental, and infectious risk factors for developing Systemic Lupus Erythematosus,” Arthritis Rheum, Vol. 41, No. 10, 1998, pp.171417-24.
|
[8]
|
V. D. D’Agati and G.B Appel, “Lupus Nephritis: Pathology and Pathogenesis,” D.J .Wallace, B.H. Hahn, eds. Dubois’ Lupus Erythematosus.7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 1094-111.
|
[9]
|
H. Zheng, Y. Chen, W. Ao, Y. Shen, X. W. Chen, M. Dai, X. D. Wang, Y. C. Yan and C. D. Yang, “Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases,” Arthritis Res Ther, Vol.11, No. 3, 2009, R93. Epub 2009 Jun 22.
|
[10]
|
J.P. Grande, “Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of enal scarring,” Lupus, Vol. 7, No. 9, 1998, pp. 604-610.
|
[11]
|
J. S. Levine, D. W. Branch and J. Rauch, “The antiphospholipid syndrome,” N Engl J Med Vol. 346, 2002, pp. 752-763.
|
[12]
|
M.L. Davies, S.P. Young, K.Welsh, M.Bunce, B.P. Wordsworth, et al., “Immune responses to native β2-glycoprotein I in patients with Systemic Lupus Erythematosus and the anti-phospholipid syndrome,” Rheumatology, Vol 41, 2002, pp. 395-400.
|
[13]
|
M. Jallouli, M. Frigui, M. B. Hmida, S. Marzouk, N. Kaddour and Z. Bahloul, “Clinical and immunological manifestations of Systemic Lupus Erythematosus: study on 146 south Tunisian patients,” Saudi J Kidney Dis Transpl, Vol. 19, No. 6, 2008, pp.1001-1008.
|
[14]
|
E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J Ninet, N. Fabien and R. Cimaz, “Pediatric Systemic Lupus Erythematosus: prognostic impact of antiphospholipid antibodies,” Rheumatology (Oxford), Vol. 47, No. 2, 2008, pp.183-187.
|
[15]
|
M. C. Hockberg, “Updating the American College of Rheumatology revised criteria for the classification of Systemic Lupus Erythematosus,” Arthritis Rheum, Vol. 40, 1997, pp. 1725.
|
[16]
|
C. Bombardier, F. F. Gladmsn, M. B. Urowit, D. Caron and C. H. Chang, “Derivation of SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arch Rheum, Vol. 35, 1995, pp. 630-640.
|
[17]
|
J. J. Weening, V. D. Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers and G. B. Appel, “The classification of glomerulonephritis in Systemic Lupus Erythematosus Re visited,” J Am Soc Nephrol, Vol.15, No. 2, 2004, pp. 241-250.
|
[18]
|
J. R. Mueh, K. D. Herbst and S. I. Rapaport, “Thrombosis in patients with the lupus anticoagulant,” Ann Intern Med. Vol. 92, No. 2, 1980, pp. 156-159.
|
[19]
|
L. O. Carreras, J. Vermylen, B. Spitz and A. Van Assche, “Lupus anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death,” Br J Obstet Gynaecol, Vol. 88, No. 9, 1981, pp.890-894.
|
[20]
|
M. L. Boey, C.B. Colaco, A. E. Gharavi, K. B. Elkon, S. Loizou and G. R. Hughes, “Thrombosis in Systemic Lupus Erythematosus: striking association with the presence of circulating lupus Anticoagulant,” Br Med J (Clin Res Ed, Vol. 8; No. 287(6398), 1983, pp. 1021-1023.
|
[21]
|
E. N. Harris, A. E. Gharavi and M. L. Boey, “Anti cardiolipin antibody detection by radioimmunoassay and association with thrombosis in Systemic Lupus Erythematosus,” Lancet, Vol. 2, 1983, pp. 1211-1214.
|
[22]
|
M. D. Lockshin and L. R. Sammaritano, “Lupus pregnancy,” Autoimmunity, Vol. 36, No. 1, 2011, pp.33-40.
|
[23]
|
G. A. Mostafa, D.H. Ibrahim, A. A. Shehab and A.K. Mohammed, “The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric Systemic Lupus Erythematosus,” J Neuroimmunol, Vol. 8, No. 227(1-2), 2010, pp.195-201.
|
[24]
|
M. Petri, “Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort,” Lupus, Vol. 19, No. 4, 2010, pp.419-423.
|
[25]
|
M. Biggioggero and P.L. Meroni, “The geoepidemiology of the antiphospholipid antibody syndrome,” Autoimmun Rev, Vol. 9, No. 5, 2010, A299-304. Epub 2009 Nov 25.
|
[26]
|
T. Gould, M. Tikly, R. Asherson, S. Loizou and S. Singh, “Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with Systemic Lupus Erythematosus,” Scand J Rheumatol, Vol. 35, No. 1, 2006, pp.29-34.
|
[27]
|
A. S. Al Arfaj and N. Khalil, “Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia,” Lupus, Vol.18, No.5, 2009, pp. 465-473.
|
[28]
|
K. S. Woo, K.E. Kim, J.M. Kim, J. Y. Han, W. T. Chung and K. H. Kim, “Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti- beta2-glycoprotein I antibodies in patients with SLE,” Korean J Lab Med, Vol 30, No. 1, 2010, pp.38-44.
|
[29]
|
A. Shrivastava, S. Dwivedi, A. Aggarwal and R. Misra, “Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with Systemic Lupus Erythematosus: association with the presence of seizures,” Lupus, Vol. 10, No. 1, 2001, pp. 45-50.
|
[30]
|
Z. S. Sarabi, E. Chang, R. Bobba, D. Ibanez, D. Gladman, M. Urowitz et al., “Incidence rates of arterial and venous thrombosis after diagnosis and Systemic Lupus Erythematosus,” Arthritis & Rheumatism, Vol. 53, No. 4, 2005, pp.609-612.
|
[31]
|
D. Erkan,“ Lupus and thrombosis,” J Rheumatol, Vol 32, 2006, pp.1715-1717.
|
[32]
|
M. Petri, M. Golbus, R. Anderson, Q. Whiting-O’Keefe, L. Corash and D. Hellmann, “Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled prospective study of forty-four women,” Arthritis Rheum, Vol 30, 1987, pp.601-606.
|